Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Male and female participants ≥4 weeks (or ≥44 weeks adjusted gestational age) to \<18 years old~* Participants hospitalized with euvolemic or hypervolemic hyponatremia resistant to initial standard background therapy~* Persistent euvolemic or hypervolemic hyponatremia defined as being documented as \<130 milliequivalent (mEq)/L and present for at least 48 hours, evidenced by at least 2 serum sodium assessments (12 hours apart)~* Ability to maintain adequate fluid intake (orally or intravenously)~* Ability to take oral medications~* Ability to comply with all requirements of the trial~* Completion of the trial-specific informed consent/assent as age appropriate~* Ability to commit to remain fully abstinent or practice double-barrier birth control as required by the trial~Exclusion:~* Evidence of hypovolemia or intravascular volume depletion~* Serum sodium \<120 mEq/L~* Use of potent cytochrome P450 3A4 (CYP3A4) inhibitors in participants \<12 kilogram (kg) or moderate CYP3A4 inhibitors in participants \<6 kg~* Lacks free access to water (inability to respond to thirst) or without intensive care unit level fluid monitoring and management~* History or current diagnosis of nephrotic syndrome~* Transient hyponatremia likely to resolve~* Hyperkalemia~* Estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared~* Acute kidney injury~* Severe or acute neurological symptoms requiring other intervention~* Prior treatment for hyponatremia with hypertonic saline within 8 hours of qualifying serum sodium assessments; urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of qualifying serum sodium assessments; any other treatments for the purpose of increasing serum sodium concurrent with dosing of trial medication~* Anuria or urinary outflow obstruction, unless participant is/can be catheterized~* History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives~* Psychogenic polydipsia~* Uncontrolled diabetes mellitus (defined as fasting glucose \>300 milligrams/deciliter)~* Screening liver function values \>3 times the upper limit of normal~* Participants who have cirrhosis and meet any of the following conditions: a major GI bleed within the past 6 months, evidence of active bleeding, platelet count \<50,000/microliter, or use of concomitant medications known to increase bleeding risk~* Hyponatremia due to the result of any medication that can safely be withdrawn or that is most appropriately corrected by alternative therapies~* History of drug or medication abuse within 3 months prior to screening or current alcohol abuse~* Participants who require suspension formulation and have a Hereditary Fructose Intolerance~* Has hyponatremia that is more appropriately corrected by alternative therapies~* Is pregnant or currently breastfeeding~* Has any medical condition that could interfere with evaluation of trial objectives or participant safety~* Has participated in another investigational drug trial in the last 30 days~* Weighs \<3 kg~* Unable to swallow tablets, if suspension unavailable~* Is deemed unsuitable for trial participation in the opinion of the investigator

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan Early Withdrawal (Type: EXPERIMENTAL): All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter \[mmol/L\]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Discontinued tolvaptan treatment immediately after randomization.~All participants were observed up to 14 days post randomization.
- Tolvaptan Late Withdrawal (Type: EXPERIMENTAL): All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Continued treatment for 2 additional days.~All participants were observed up to 14 days post randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).